Detailed price information for Icecure Medical Ltd Ord (ICCM-Q) from The Globe and Mail including charting and trades.

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

IceCure Medical Ltd. announced that four abstracts featuring data from independent clinical studies conducted in Spain and ...

Detailed price information for Icecure Medical Ltd Ord (ICCM-Q) from The Globe and Mail including charting and trades.

Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense (R) ...

Lumpectomy has been the standard of care for low-risk, early-stage breast cancer, but now cryoablation — freezing cancer tumors to kill them — is emerging as a new option. The FDA recently granted ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...

PHOENIX (AZFamily) — There’s a new kind of breast cancer treatment that involves no chemotherapy, no radiation, and no surgery. It may seem to good to be true, but this Breast Cancer Awareness month, ...

The ProSense® Cryoablation System could be a game changer for women over 70 with early-stage, low-risk breast cancer. For decades, breast cancer treatment has often meant surgery, which can be an ...